There is currently no approved drug on the market that treats the core symptoms of Autism. At Curemark, we are working to change that.
Curemark’s lead drug candidate, CM-AT, has received “Fast Track” designation from the U.S. Food and Drug Administration (FDA) and FDA has granted Curemark a rolling review of its New Drug Application for CM-AT.
LEARN MORE
5.4 million children in the U.S., aged 4-17 years old (or 3-9% of school aged population) have been diagnosed with Attention-Deficit Hyperactivity Disorder (ADHD)—characterized by inattention, hyperactivity and impulsivity.
LEARN MORE
Our drug candidate, CM-1212, seeks to treat alcohol and drug addiction. Individuals addicted to drugs and alcohol lack the ability to properly digest and absorb essential nutrients. Emerging research indicates a role for amino acids in the persistence of addictive behaviors.
LEARN MORE
Although no cure exists for Parkinson’s disease (PD), various medications, surgeries, and physical therapies can help improve symptoms and reduce the disease’s progression.
Our drug candidate, CM-PK, may be able to affect dopamine levels in PD patients while also improving postural instability and reducing falls.
LEARN MORE
The current treatment for schizophrenia, antipsychotics, can lead to numerous side effects, including drowsiness, dizziness, and rapid heartbeat.
We are developing an enzyme replacement therapy, CM-182, that may be helpful in the treatment of schizophrenia. Animal model studies of CM-182 have shown effectiveness in treating the positive symptoms of schizophrenia without sedation.
LEARN MORECuremark has built a broad pipeline of drug products that addresses an array of disorders. Our lead drug candidate is in a Phase III clinical trial for Autism and our other drug candidates are in pre-clinical research or are clinic-ready. Read more about these product candidates.
